Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Peripartum cardiomyopathy (PPCM) is a cause of pregnancy-associated heart failure. It typically develops during the last month of, and up to 6 months after, pregnancy in women without known cardiovascular disease. The present position statement offers a state-of-the-art summary of what is known about risk factors for potential pathophysiological mechanisms, clinical presentation of, and diagnosis and management of PPCM. A high index of suspicion is required for the diagnosis, as shortness of breath and ankle swelling are common in the peripartum period. Peripartum cardiomyopathy is a distinct form of cardiomyopathy, associated with a high morbidity and mortality, but also with the possibility of full recovery. Oxidative stress and the generation of a cardiotoxic subfragment of prolactin may play key roles in the pathophysiology of PPCM. In this regard, pharmacological blockade of prolactin offers the possibility of a disease-specific therapy.

Original publication

DOI

10.1093/eurjhf/hfq120

Type

Journal article

Journal

Eur J Heart Fail

Publication Date

08/2010

Volume

12

Pages

767 - 778

Keywords

Antihypertensive Agents, Cardiology, Cardiomyopathies, Cathepsin D, Europe, Female, Humans, Incidence, Inflammation, Natriuretic Peptide, Brain, Oxidative Stress, Postpartum Period, Pregnancy, Pregnancy Complications, Prognosis, Prolactin, Risk Factors, Societies, Medical